MDGL MADRIGAL PHARMACEUTICALS INC Product Launches 8-K Filing 2023 - FDA Acceptance of New Drug Application Madrigal Pharmaceuticals announced that the FDA has accepted their New Drug Application for resmetirom for the treatment of NASH with liver fibrosis and granted a Priority Review designation.Get access to all SEC 8-K filings of the MADRIGAL PHARMACEUTICALS INC